Advanced glycation end products are elevated in estrogen receptor-positive breast cancer patients, alter response to therapy, and can be targeted by lifestyle intervention

Authors

Katherine R. Walter, Medical University of South Carolina
Lindsay L. Peterson, Washington University School of Medicine in St. Louis
et al

Journal

Breast Cancer Research and Treatment

Publication Date

2019

Volume

173

Issue

3

First Page

559

Last Page

571

Document Type

Open Access Publication

DOI

10.1007/s00125-016-4053-x

Rights and Permissions

Walter, K.R., Ford, M.E., Gregoski, M.J. et al. Breast Cancer Res Treat (2019) 173: 559. https://doi.org/10.1007/s10549-018-4992-7 © The Author(s) 2018 This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Recommended Citation

Walter, Katherine R.; Peterson, Lindsay L.; and et al, "Advanced glycation end products are elevated in estrogen receptor-positive breast cancer patients, alter response to therapy, and can be targeted by lifestyle intervention." Breast Cancer Research and Treatment. 173, 3. 559 - 571. (2019).
https://digitalcommons.wustl.edu/open_access_pubs/8218